4,5-dimethyl-2-(p-tolyl)oxazole 3-oxide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4,5-dimethyl-2-(p-tolyl)oxazole 3-oxide
• 英文别名: 4,5-Dimethyl-2-p-tolyl-oxazole 3-oxide；4,5-dimethyl-2-(4-methylphenyl)-3-oxido-1,3-oxazol-3-ium
• 化学式: C₁₂H₁₃NO₂
• 分子量: 203.241
• InChiKey: JHWYQVITAXLLKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,5-dimethyl-2-(p-tolyl)oxazole 3-oxide 在 三氯氧磷 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 4-(氯甲基)-5-甲基-2-(4-甲基苯)-1,3-恶唑
  参考文献：
  名称：

  1,3-恶唑异烟肼杂化物：合成，抗结核活性及其对接研究

  摘要：

  通过2-芳基-5-甲基的缩合反应制备了一系列新型的N '-（[[2-芳基-5-甲基-1,3-恶唑-4-基]亚甲基]异烟肼/烟碱酰肼10a-1。 -1,3-恶唑-4-甲醛8a-f和相应的异烟肼/烟碱酰肼9a / 9b。通过各种光谱分析技术阐明了新化合物的结构，包括IR，1 H NMR，13 C NMR，元素（C，H，N）和质量分析。所有新制备的INH基-1,3-唑杂交种的评价在 体外对抗结核活性结核分枝杆菌分枝杆菌。在所有合成的杂种中，化合物10c和10i衍生物显示出最高的抗结核活性，最小抑菌浓度为1.56μg/ mL。此外，进行了针对InhA酶的分子对接研究，以了解有效杂种与目标酶之间的相互作用。因此，这些杂种具有发现新的抗结核药物用于控制和根除结核病的潜力。

  DOI：

  10.1002/jhet.3893
• 作为产物：
  描述：

  对甲基苯甲醛 、 二乙酰一肟 在 盐酸 作用下， 以 1,4-二氧六环 、 溶剂黄146 为溶剂， 反应 16.0h， 以47%的产率得到4,5-dimethyl-2-(p-tolyl)oxazole 3-oxide
  参考文献：
  名称：

  Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle

  摘要：

  Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of Iii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.

  DOI：

  10.1021/acs.jmedchem.7b00561

文献信息

• SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD
  申请人：Cheng T.W. Peter

  公开号：US20080009534A1

  公开（公告）日：2008-01-10

  Compounds are provided which have the structure of Formula (I): wherein R is hydrogen or C 1 -C 4 alkyl; and each of R 1 and R 2 is independently hydrogen, C 1 -C 4 alkyl, halo or C 1 -C 4 alkoxy, and salts thereof, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

  提供具有以下结构的化合物（I）：其中R为氢或C1-C4烷基；R1和R2中的每一个独立地为氢、C1-C4烷基、卤素或C1-C4甲氧基，以及它们的盐，这些化合物可用作抗糖尿病、降脂和抗肥胖药物。
• Process for the preparation of the PPAR alpha agonist NS-220
  申请人：Hartung Thomas

  公开号：US20070197615A1

  公开（公告）日：2007-08-23

  The present invention is concerned with a novel process for the preparation of compounds of formula (I) wherein R 1 and R 2 are as defined in the description and claims. The compounds of formula (I) are pharmaceutically active substances.

  本发明涉及一种新型制备式（I）化合物的方法，其中R1和R2如描述和索赔中所定义。式（I）化合物是具有药用活性的物质。
• SUBSTITUTED ARYLOXAZOLES AND THEIR USE
  申请人：Nell Peter

  公开号：US20110130377A1

  公开（公告）日：2011-06-02

  The present application relates to novel substituted aryloxazole derivatives, a method for the production thereof, the use thereof for the treatment and/or prophylaxis of diseases and the use thereof for the production of drugs for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

  本申请涉及新型取代芳氧唑衍生物，其生产方法，用于治疗和/或预防疾病的用途，以及用于生产用于治疗和/或预防疾病的药物的用途，优选用于治疗和/或预防心血管和代谢紊乱。
• METHOD FOR THE PREPARATION OF OXAZOLES BY CONDENSING AROMATIC ALDEHYDES WITH ALPHA-KETOXIMES TO FORM N-OXIDES AND REACTING SAME WITH ACTIVATIVED ACID DERIVATIVES
  申请人：HOLLA Wolfgang

  公开号：US20080058529A1

  公开（公告）日：2008-03-06

  The present invention is comprised of improved methods in the preparation of oxazoles which results in higher yields with less impurities and contaminants. Oxazoles constitute valuable intermediates in the synthesis of pharmaceutically active substances such as, for example peroxisome proliferator activated receptor (PPAR) agonists which are pharmaceutical actives which can have a positive influence on both lipid and glucose metabolism.

  本发明涉及改进的制备噁唑的方法，其结果是产量更高，杂质和污染物更少。噁唑是合成药物活性物质的有价值的中间体，例如过氧化物酶体增殖物激活受体（PPAR）激动剂，这些药物活性物质可以对脂质和葡萄糖代谢产生积极影响。
• NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PREPARATION OF OXAZOLES AND PHARMACEUTICAL ACTIVES FOR THE REGULATION OF LIPID AND GLUCOSE METABOLISM
  申请人：HOLLA Wolfgang

  公开号：US20080114035A1

  公开（公告）日：2008-05-15

  The present invention is directed to compounds of Formula III wherein the R1-R7 groups or substituents are defined herein. The present invention also comprises improved methods in the preparation of oxazoles in which the compounds of Formula III are intermediates and which results in higher yields with less impurities and contaminants. Oxazoles constitute valuable intermediates in the synthesis of pharmaceutically active substances such as, for example peroxisome proliferator activated receptor (PPAR) agonists which are pharmaceutical actives which can have a positive influence on both lipid and glucose metabolism.

  本发明涉及式III的化合物，其中R1-R7基团或取代基如本文所定义。本发明还包括改进的制备噁唑的方法，其中式III的化合物是中间体，并且可以获得更高的收率，同时减少杂质和污染物。噁唑是合成药物活性物质的有价值中间体，例如过氧化物酶体增殖物激活受体（PPAR）激动剂，这是一种药物活性物质，可以对脂质和葡萄糖代谢产生积极影响。